biostudies-literatureUnknown20(32)Hamilton EPArvinas Estrogen Receptor, Inc.Pfizer, Inc.Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human Phase I/II study, vepdegestrant monotherapy was well tolerated with clinical activity in pretreated patients with ER+/HER2- advanced breast cancer. The global, randomized Phase III VERITAC-2 study compares efficacy and safety of vepdegestrant versus fulvestrant in adults with ER+/HER2- advanced breast cancer after treatment with a CDK4/6 inhibitor plus endocrine therapy. Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and <i>ESR1</i> mutation-positive subpopulation. Secondary end points include overall suFuture oncology (London, England)2447-2455https://www.ebi.ac.uk/biostudies/studies/S-EPMC11524203biostudies-literatureVERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.PMC11524203Perkins Smith JDe Laurentiis MLu DRCampone MWander SAAnderson SHamilton EPHurvitz SADanso MIwata HLiu YMa CTran LfalseVERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human Phase I/II study, vepdegestrant monotherapy was well tolerated with clinical activity in pretreated patients with ER+/HER2- advanced breast cancer. The global, randomized Phase III VERITAC-2 study compares efficacy and safety of vepdegestrant versus fulvestrant in adults with ER+/HER2- advanced breast cancer after treatment with a CDK4/6 inhibitor plus endocrine therapy. Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and <i>ESR1</i> mutation-positive subpopulation. Secondary end points include overall su2024-01-01T00:00:00Z20242026-07-15T17:41:11.767Z2025-04-04T00:29:51.186ZS-EPMC115242033907235610.1080/14796694.2024.2377530